1. Historical Perspective on Clinical Trials of Carnitine in Children and Adults.
- Author
-
Buist NR
- Subjects
- Administration, Intravenous, Adult, Cardiomyopathies diet therapy, Cardiomyopathies history, Cardiomyopathies physiopathology, Carnitine administration & dosage, Carnitine adverse effects, Carnitine history, Carnitine Acyltransferases deficiency, Carnitine Acyltransferases history, Child, Clinical Trials as Topic, Deficiency Diseases diet therapy, Deficiency Diseases history, Deficiency Diseases physiopathology, Energy Metabolism, History, 20th Century, History, 21st Century, Humans, Hyperammonemia diet therapy, Hyperammonemia history, Hyperammonemia physiopathology, Infant, Lipid Metabolism, Inborn Errors diet therapy, Lipid Metabolism, Inborn Errors drug therapy, Lipid Metabolism, Inborn Errors history, Lipid Metabolism, Inborn Errors physiopathology, Metabolism, Inborn Errors drug therapy, Metabolism, Inborn Errors history, Metabolism, Inborn Errors physiopathology, Muscular Diseases diet therapy, Muscular Diseases history, Muscular Diseases physiopathology, Orphan Drug Production history, Cardiomyopathies prevention & control, Carnitine deficiency, Carnitine therapeutic use, Child Nutrition Sciences history, Deficiency Diseases prevention & control, Dietary Supplements adverse effects, Hyperammonemia prevention & control, Metabolism, Inborn Errors diet therapy, Muscular Diseases prevention & control, Nutritional Sciences history
- Abstract
The metabolic roles of carnitine have been greatly clarified over the past 50 years, and it is now well established that carnitine is a key player in mitochondrial generation of energy and metabolism of acetyl coenzyme A. A therapeutic role for carnitine in treatment of nutritional deficiencies in infants and children was first demonstrated in 1958, and since that time it has been used to treat a number of inborn errors of metabolism. Carnitine was approved by the US Food and Drug Administration in 1985 for treatment of 'primary carnitine deficiency', and later in 1992 for treatment of 'secondary carnitine deficiency', a definition that included the majority of relevant metabolic disorders associated with low or abnormal plasma carnitine levels. Today, carnitine treatment of inborn errors of metabolism is a safe and integral part of many treatment protocols, and a growing interest in carnitine has resulted in greater recognition of many causes of carnitine depletion. Notwithstanding, there is still a lack of data from randomized clinical trials, even on the use of carnitine in inborn errors of metabolism, although ethical issues may be a contributing factor in this regard., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF